APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nano Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nano Antibodies Market Outlook and Growth Opportunities 2026

20 December 2025202 pages

Choose your research edition.

Industry ResearchNano Antibodies Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Nano Antibodies Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Nano Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nano Antibodies Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Nano Antibodies Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Nano Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nano Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nano Antibodies market include Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), Alphamab Oncology, Beroni Group, ChromoTek GmbH, Cusabio Technology LLC., DiosCURE Therapeutics SE, ExeVir Bio BV and Genscript, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nano Antibodies market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nano Antibodies and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nano Antibodies revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nano Antibodies market.

Nano Antibodies Segment by Company

Absolute Antibody

Alpalife (Shenzhen kangti Co., Ltd.)

Alphamab Oncology

Beroni Group

ChromoTek GmbH

Cusabio Technology LLC.

DiosCURE Therapeutics SE

ExeVir Bio BV

Genscript

PerkinElmer Inc. (BioLegend, Inc.)

Sensei Biotherapeutics, Inc.

Taisho Pharmaceutical Holdings

Merck KGaA

Novartis AG

Thermo Fisher Scientific Inc.

Sanofi (Ablynx)

Nano Antibodies Segment by Type

Fusion Nanobody

Multivalent and multispecific Nanobodies

Monovalent Nanobody

Nano Antibodies Segment by Application

Tumor targeted therapy

Circulatory disease

Disease detection in vitro

Non-invasive diagnosis in vivo

Nervous system disease

Infectious disease

Other

Nano Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Nano Antibodies status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nano Antibodies key companies, revenue, market share, and recent developments.

3. To split the Nano Antibodies breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nano Antibodies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nano Antibodies significant trends, drivers, influence factors in global and regions.

6. To analyze Nano Antibodies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nano Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nano Antibodies industry.

Chapter 3: Detailed analysis of Nano Antibodies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nano Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nano Antibodies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nano Antibodies Industry Trends Table 2. Nano Antibodies Industry Drivers Table 3. Nano Antibodies Industry Opportunities and Challenges Table 4. Nano Antibodies Industry Restraints Table 5. Global Nano Antibodies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nano Antibodies Revenue Share by Company (2021-2026) Table 7. Global Nano Antibodies Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nano Antibodies Key Company Manufacturing Base & Headquarters Table 9. Global Nano Antibodies Company, Product Type & Application Table 10. Global Nano Antibodies Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nano Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Fusion Nanobody Table 15. Significant Companies of Multivalent and multispecific Nanobodies Table 16. Significant Companies of Monovalent Nanobody Table 17. Global Nano Antibodies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Nano Antibodies Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Nano Antibodies Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Nano Antibodies Sales Value Share by Type (2021-2026) Table 21. Global Nano Antibodies Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Tumor targeted therapy Table 23. Significant Companies of Circulatory disease Table 24. Significant Companies of Disease detection in vitro Table 25. Significant Companies of Non-invasive diagnosis in vivo Table 26. Significant Companies of Nervous system disease Table 27. Significant Companies of Infectious disease Table 28. Significant Companies of Other Table 29. Global Nano Antibodies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Nano Antibodies Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Nano Antibodies Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Nano Antibodies Sales Value Share by Application (2021-2026) Table 33. Global Nano Antibodies Sales Value Share by Application (2027-2032) Table 34. Global Nano Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Nano Antibodies Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Nano Antibodies Sales Value Share by Region (2021-2026) Table 37. Global Nano Antibodies Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Nano Antibodies Sales Value Share by Region (2027-2032) Table 39. Global Nano Antibodies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Nano Antibodies Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Nano Antibodies Sales Value Market Share by Country (2021-2026) Table 42. Global Nano Antibodies Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Nano Antibodies Sales Value Market Share by Country (2027-2032) Table 44. Absolute Antibody Company Information Table 45. Absolute Antibody Business Overview Table 46. Absolute Antibody Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Absolute Antibody Nano Antibodies Product Portfolio Table 48. Absolute Antibody Recent Development Table 49. Alpalife (Shenzhen kangti Co., Ltd.) Company Information Table 50. Alpalife (Shenzhen kangti Co., Ltd.) Business Overview Table 51. Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio Table 53. Alpalife (Shenzhen kangti Co., Ltd.) Recent Development Table 54. Alphamab Oncology Company Information Table 55. Alphamab Oncology Business Overview Table 56. Alphamab Oncology Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Alphamab Oncology Nano Antibodies Product Portfolio Table 58. Alphamab Oncology Recent Development Table 59. Beroni Group Company Information Table 60. Beroni Group Business Overview Table 61. Beroni Group Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Beroni Group Nano Antibodies Product Portfolio Table 63. Beroni Group Recent Development Table 64. ChromoTek GmbH Company Information Table 65. ChromoTek GmbH Business Overview Table 66. ChromoTek GmbH Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. ChromoTek GmbH Nano Antibodies Product Portfolio Table 68. ChromoTek GmbH Recent Development Table 69. Cusabio Technology LLC. Company Information Table 70. Cusabio Technology LLC. Business Overview Table 71. Cusabio Technology LLC. Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Cusabio Technology LLC. Nano Antibodies Product Portfolio Table 73. Cusabio Technology LLC. Recent Development Table 74. DiosCURE Therapeutics SE Company Information Table 75. DiosCURE Therapeutics SE Business Overview Table 76. DiosCURE Therapeutics SE Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. DiosCURE Therapeutics SE Nano Antibodies Product Portfolio Table 78. DiosCURE Therapeutics SE Recent Development Table 79. ExeVir Bio BV Company Information Table 80. ExeVir Bio BV Business Overview Table 81. ExeVir Bio BV Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. ExeVir Bio BV Nano Antibodies Product Portfolio Table 83. ExeVir Bio BV Recent Development Table 84. Genscript Company Information Table 85. Genscript Business Overview Table 86. Genscript Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Genscript Nano Antibodies Product Portfolio Table 88. Genscript Recent Development Table 89. PerkinElmer Inc. (BioLegend, Inc.) Company Information Table 90. PerkinElmer Inc. (BioLegend, Inc.) Business Overview Table 91. PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio Table 93. PerkinElmer Inc. (BioLegend, Inc.) Recent Development Table 94. Sensei Biotherapeutics, Inc. Company Information Table 95. Sensei Biotherapeutics, Inc. Business Overview Table 96. Sensei Biotherapeutics, Inc. Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio Table 98. Sensei Biotherapeutics, Inc. Recent Development Table 99. Taisho Pharmaceutical Holdings Company Information Table 100. Taisho Pharmaceutical Holdings Business Overview Table 101. Taisho Pharmaceutical Holdings Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio Table 103. Taisho Pharmaceutical Holdings Recent Development Table 104. Merck KGaA Company Information Table 105. Merck KGaA Business Overview Table 106. Merck KGaA Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Merck KGaA Nano Antibodies Product Portfolio Table 108. Merck KGaA Recent Development Table 109. Novartis AG Company Information Table 110. Novartis AG Business Overview Table 111. Novartis AG Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Novartis AG Nano Antibodies Product Portfolio Table 113. Novartis AG Recent Development Table 114. Thermo Fisher Scientific Inc. Company Information Table 115. Thermo Fisher Scientific Inc. Business Overview Table 116. Thermo Fisher Scientific Inc. Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio Table 118. Thermo Fisher Scientific Inc. Recent Development Table 119. Sanofi (Ablynx) Company Information Table 120. Sanofi (Ablynx) Business Overview Table 121. Sanofi (Ablynx) Nano Antibodies Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Sanofi (Ablynx) Nano Antibodies Product Portfolio Table 123. Sanofi (Ablynx) Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Nano Antibodies Product Image Figure 2. Global Nano Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nano Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Nano Antibodies Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Fusion Nanobody Image Figure 8. Multivalent and multispecific Nanobodies Image Figure 9. Monovalent Nanobody Image Figure 10. Global Nano Antibodies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Nano Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Nano Antibodies Sales Value Share by Type (2021-2032) Figure 13. Tumor targeted therapy Image Figure 14. Circulatory disease Image Figure 15. Disease detection in vitro Image Figure 16. Non-invasive diagnosis in vivo Image Figure 17. Nervous system disease Image Figure 18. Infectious disease Image Figure 19. Other Image Figure 20. Global Nano Antibodies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Nano Antibodies Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Nano Antibodies Sales Value Share by Application (2021-2032) Figure 23. Global Nano Antibodies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Nano Antibodies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Nano Antibodies Sales Value (2021-2032) & (US$ Million) Figure 26. North America Nano Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Nano Antibodies Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Nano Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Nano Antibodies Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Nano Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Nano Antibodies Sales Value (2021-2032) & (US$ Million) Figure 32. South America Nano Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Nano Antibodies Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Nano Antibodies Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Nano Antibodies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Nano Antibodies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Nano Antibodies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Nanobody
  • Multivalent and multispecific Nanobodies
  • Monovalent Nanobody
Applications
  • Tumor targeted therapy
  • Circulatory disease
  • Disease detection in vitro
  • Non-invasive diagnosis in vivo
  • Nervous system disease
  • Infectious disease
  • Other
Companies covered
  • Absolute Antibody
  • Alpalife (Shenzhen kangti Co., Ltd.)
  • Alphamab Oncology
  • Beroni Group
  • ChromoTek GmbH
  • Cusabio Technology LLC.
  • DiosCURE Therapeutics SE
  • ExeVir Bio BV
  • Genscript
  • PerkinElmer Inc. (BioLegend, Inc.)
  • Sensei Biotherapeutics, Inc.
  • Taisho Pharmaceutical Holdings
  • Merck KGaA
  • Novartis AG
  • Thermo Fisher Scientific Inc.
  • Sanofi (Ablynx)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nano Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nano Antibodies Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nano Antibodies Market Dynamics
  1. 2.1 Nano Antibodies Industry Trends
  2. 2.2 Nano Antibodies Industry Drivers
  3. 2.3 Nano Antibodies Industry Opportunities and Challenges
  4. 2.4 Nano Antibodies Industry Restraints
3 Nano Antibodies Market by Company
  1. 3.1 Global Nano Antibodies Company Revenue Ranking in 2025
  2. 3.2 Global Nano Antibodies Revenue by Company (2021-2026)
  3. 3.3 Global Nano Antibodies Company Ranking (2024-2026)
  4. 3.4 Global Nano Antibodies Company Manufacturing Base and Headquarters
  5. 3.5 Global Nano Antibodies Company Product Type and Application
  6. 3.6 Global Nano Antibodies Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nano Antibodies Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nano Antibodies Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nano Antibodies Market by Type
  1. 4.1 Nano Antibodies Type Introduction
  2. 4.1.1 Fusion Nanobody
  3. 4.1.2 Multivalent and multispecific Nanobodies
  4. 4.1.3 Monovalent Nanobody
  5. 4.2 Global Nano Antibodies Sales Value by Type
  6. 4.2.1 Global Nano Antibodies Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Nano Antibodies Sales Value by Type (2021-2032)
  8. 4.2.3 Global Nano Antibodies Sales Value Share by Type (2021-2032)
5 Nano Antibodies Market by Application
  1. 5.1 Nano Antibodies Application Introduction
  2. 5.1.1 Tumor targeted therapy
  3. 5.1.2 Circulatory disease
  4. 5.1.3 Disease detection in vitro
  5. 5.1.4 Non-invasive diagnosis in vivo
  6. 5.1.5 Nervous system disease
  7. 5.1.6 Infectious disease
  8. 5.1.7 Other
  9. 5.2 Global Nano Antibodies Sales Value by Application
  10. 5.2.1 Global Nano Antibodies Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Nano Antibodies Sales Value by Application (2021-2032)
  12. 5.2.3 Global Nano Antibodies Sales Value Share by Application (2021-2032)
6 Nano Antibodies Regional Value Analysis
  1. 6.1 Global Nano Antibodies Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nano Antibodies Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nano Antibodies Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nano Antibodies Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nano Antibodies Sales Value (2021-2032)
  7. 6.3.2 North America Nano Antibodies Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nano Antibodies Sales Value (2021-2032)
  10. 6.4.2 Europe Nano Antibodies Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nano Antibodies Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nano Antibodies Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nano Antibodies Sales Value (2021-2032)
  16. 6.6.2 South America Nano Antibodies Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nano Antibodies Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nano Antibodies Sales Value Share by Country, 2025 VS 2032
7 Nano Antibodies Country-level Value Analysis
  1. 7.1 Global Nano Antibodies Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nano Antibodies Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nano Antibodies Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nano Antibodies Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nano Antibodies Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nano Antibodies Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nano Antibodies Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nano Antibodies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nano Antibodies Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nano Antibodies Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nano Antibodies Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nano Antibodies Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nano Antibodies Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nano Antibodies Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nano Antibodies Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nano Antibodies Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nano Antibodies Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nano Antibodies Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nano Antibodies Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nano Antibodies Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nano Antibodies Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nano Antibodies Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nano Antibodies Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nano Antibodies Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nano Antibodies Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nano Antibodies Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nano Antibodies Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nano Antibodies Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nano Antibodies Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nano Antibodies Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nano Antibodies Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nano Antibodies Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nano Antibodies Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nano Antibodies Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nano Antibodies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Absolute Antibody
  2. 8.1.1 Absolute Antibody Company Information
  3. 8.1.2 Absolute Antibody Business Overview
  4. 8.1.3 Absolute Antibody Nano Antibodies Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Absolute Antibody Nano Antibodies Product Portfolio
  6. 8.1.5 Absolute Antibody Recent Developments
  7. 8.2 Alpalife (Shenzhen kangti Co., Ltd.)
  8. 8.2.1 Alpalife (Shenzhen kangti Co., Ltd.) Company Information
  9. 8.2.2 Alpalife (Shenzhen kangti Co., Ltd.) Business Overview
  10. 8.2.3 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio
  12. 8.2.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments
  13. 8.3 Alphamab Oncology
  14. 8.3.1 Alphamab Oncology Company Information
  15. 8.3.2 Alphamab Oncology Business Overview
  16. 8.3.3 Alphamab Oncology Nano Antibodies Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Alphamab Oncology Nano Antibodies Product Portfolio
  18. 8.3.5 Alphamab Oncology Recent Developments
  19. 8.4 Beroni Group
  20. 8.4.1 Beroni Group Company Information
  21. 8.4.2 Beroni Group Business Overview
  22. 8.4.3 Beroni Group Nano Antibodies Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Beroni Group Nano Antibodies Product Portfolio
  24. 8.4.5 Beroni Group Recent Developments
  25. 8.5 ChromoTek GmbH
  26. 8.5.1 ChromoTek GmbH Company Information
  27. 8.5.2 ChromoTek GmbH Business Overview
  28. 8.5.3 ChromoTek GmbH Nano Antibodies Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ChromoTek GmbH Nano Antibodies Product Portfolio
  30. 8.5.5 ChromoTek GmbH Recent Developments
  31. 8.6 Cusabio Technology LLC.
  32. 8.6.1 Cusabio Technology LLC. Company Information
  33. 8.6.2 Cusabio Technology LLC. Business Overview
  34. 8.6.3 Cusabio Technology LLC. Nano Antibodies Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cusabio Technology LLC. Nano Antibodies Product Portfolio
  36. 8.6.5 Cusabio Technology LLC. Recent Developments
  37. 8.7 DiosCURE Therapeutics SE
  38. 8.7.1 DiosCURE Therapeutics SE Company Information
  39. 8.7.2 DiosCURE Therapeutics SE Business Overview
  40. 8.7.3 DiosCURE Therapeutics SE Nano Antibodies Revenue and Gross Margin (2021-2026)
  41. 8.7.4 DiosCURE Therapeutics SE Nano Antibodies Product Portfolio
  42. 8.7.5 DiosCURE Therapeutics SE Recent Developments
  43. 8.8 ExeVir Bio BV
  44. 8.8.1 ExeVir Bio BV Company Information
  45. 8.8.2 ExeVir Bio BV Business Overview
  46. 8.8.3 ExeVir Bio BV Nano Antibodies Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ExeVir Bio BV Nano Antibodies Product Portfolio
  48. 8.8.5 ExeVir Bio BV Recent Developments
  49. 8.9 Genscript
  50. 8.9.1 Genscript Company Information
  51. 8.9.2 Genscript Business Overview
  52. 8.9.3 Genscript Nano Antibodies Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genscript Nano Antibodies Product Portfolio
  54. 8.9.5 Genscript Recent Developments
  55. 8.10 PerkinElmer Inc. (BioLegend, Inc.)
  56. 8.10.1 PerkinElmer Inc. (BioLegend, Inc.) Company Information
  57. 8.10.2 PerkinElmer Inc. (BioLegend, Inc.) Business Overview
  58. 8.10.3 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio
  60. 8.10.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments
  61. 8.11 Sensei Biotherapeutics, Inc.
  62. 8.11.1 Sensei Biotherapeutics, Inc. Company Information
  63. 8.11.2 Sensei Biotherapeutics, Inc. Business Overview
  64. 8.11.3 Sensei Biotherapeutics, Inc. Nano Antibodies Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio
  66. 8.11.5 Sensei Biotherapeutics, Inc. Recent Developments
  67. 8.12 Taisho Pharmaceutical Holdings
  68. 8.12.1 Taisho Pharmaceutical Holdings Company Information
  69. 8.12.2 Taisho Pharmaceutical Holdings Business Overview
  70. 8.12.3 Taisho Pharmaceutical Holdings Nano Antibodies Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio
  72. 8.12.5 Taisho Pharmaceutical Holdings Recent Developments
  73. 8.13 Merck KGaA
  74. 8.13.1 Merck KGaA Company Information
  75. 8.13.2 Merck KGaA Business Overview
  76. 8.13.3 Merck KGaA Nano Antibodies Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck KGaA Nano Antibodies Product Portfolio
  78. 8.13.5 Merck KGaA Recent Developments
  79. 8.14 Novartis AG
  80. 8.14.1 Novartis AG Company Information
  81. 8.14.2 Novartis AG Business Overview
  82. 8.14.3 Novartis AG Nano Antibodies Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Novartis AG Nano Antibodies Product Portfolio
  84. 8.14.5 Novartis AG Recent Developments
  85. 8.15 Thermo Fisher Scientific Inc.
  86. 8.15.1 Thermo Fisher Scientific Inc. Company Information
  87. 8.15.2 Thermo Fisher Scientific Inc. Business Overview
  88. 8.15.3 Thermo Fisher Scientific Inc. Nano Antibodies Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio
  90. 8.15.5 Thermo Fisher Scientific Inc. Recent Developments
  91. 8.16 Sanofi (Ablynx)
  92. 8.16.1 Sanofi (Ablynx) Company Information
  93. 8.16.2 Sanofi (Ablynx) Business Overview
  94. 8.16.3 Sanofi (Ablynx) Nano Antibodies Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sanofi (Ablynx) Nano Antibodies Product Portfolio
  96. 8.16.5 Sanofi (Ablynx) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst